Exelixis | Salg Og Administrasjonskostnader



Selling And Administration Expenses Endring Dato
Acadia Pharmaceuticals USD 130.08M 3.21M 2024-12
Agios Pharmaceuticals USD 51.7M 13.16M 2024-12
Amgen USD 1.88B 253M 2024-12
AstraZeneca USD 5.55B 307M 2024-12
Bayer EUR 4.34B 610M 2024-12
BioMarin Pharmaceutical USD 256.77M 46.81M 2024-12
Bristol-Myers Squibb USD 2.1B 129M 2024-12
Cytokinetics USD 62.34M 5.69M 2024-12
Eisai JPY 104.52B 7.1B 2024-12
Eli Lilly USD 2.42B 324.7M 2024-12
Exelixis USD 134.33M 22.53M 2025-01
Genmab DKK 1.25B 384M 2024-12
Glaxosmithkline GBP 2.7B 632M 2024-12
Incyte USD 326.71M 17.5M 2024-12
Ionis Pharmaceuticals USD 88.08M 26.44M 2024-12
MacroGenics USD 27.81M 13.71M 2024-12
Merck USD 2.85B 148M 2024-12
Moderna USD 351M 70M 2024-12
Neurocrine Biosciences USD 287.8M 53.5M 2024-12
Novartis USD 3.5B 368M 2024-12
Pfizer USD 4.27B 1.06B 2024-12
Sanofi EUR 1.24B 1.44B 2024-12
Takeda JPY 270.59B 2.31B 2024-12
Ultragenyx Pharmaceutical USD 82.49M 2.14M 2024-12
Xencor USD 14.92M 148K 2024-12



Exelixis Salg Og Administrasjonskostnader - Gjeldende verdier, historiske data, prognoser, statistikk, diagrammer og økonomiske kalender - Apr 2025.